Mather Group LLC. Raises Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Mather Group LLC. lifted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 30.7% during the second quarter, Holdings Channel reports. The institutional investor owned 3,174 shares of the medical research company’s stock after acquiring an additional 745 shares during the quarter. Mather Group LLC.’s holdings in Thermo Fisher Scientific were worth $1,845,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. LifeSteps Financial Inc. bought a new position in Thermo Fisher Scientific during the 1st quarter valued at approximately $31,000. Northwest Financial Advisors bought a new position in Thermo Fisher Scientific in the 4th quarter worth about $29,000. True Wealth Design LLC increased its stake in Thermo Fisher Scientific by 1,275.0% during the 4th quarter. True Wealth Design LLC now owns 55 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 51 shares in the last quarter. Headlands Technologies LLC purchased a new position in Thermo Fisher Scientific in the first quarter worth about $32,000. Finally, Bank & Trust Co purchased a new stake in shares of Thermo Fisher Scientific during the second quarter valued at approximately $33,000. Institutional investors own 89.23% of the company’s stock.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $180,255.00. Following the sale, the executive vice president now owns 17,887 shares of the company’s stock, valued at approximately $10,747,403.95. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $600.85, for a total value of $180,255.00. Following the sale, the executive vice president now directly owns 17,887 shares in the company, valued at approximately $10,747,403.95. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $70,238,340.48. The disclosure for this sale can be found here. Insiders have sold a total of 33,084 shares of company stock worth $19,767,092 in the last 90 days. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Price Performance

Shares of TMO traded up $4.00 during trading hours on Tuesday, reaching $602.03. 1,316,851 shares of the stock traded hands, compared to its average volume of 1,567,578. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $622.30. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64. The company has a market cap of $229.80 billion, a P/E ratio of 39.08, a price-to-earnings-growth ratio of 2.87 and a beta of 0.77. The company’s 50-day moving average price is $565.80 and its two-hundred day moving average price is $568.84.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The firm had revenue of $10.54 billion during the quarter, compared to analysts’ expectations of $10.50 billion. During the same quarter last year, the business posted $5.15 earnings per share. The firm’s revenue was down 1.4% on a year-over-year basis. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 21.71 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Friday, September 13th will be issued a $0.39 dividend. The ex-dividend date of this dividend is Friday, September 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Raymond James upped their price objective on Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. Robert W. Baird lifted their price objective on Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Jefferies Financial Group reaffirmed a “buy” rating and set a $650.00 price target (up previously from $600.00) on shares of Thermo Fisher Scientific in a report on Monday, June 3rd. TD Cowen boosted their price objective on shares of Thermo Fisher Scientific from $648.00 to $658.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Finally, Stifel Nicolaus lifted their target price on shares of Thermo Fisher Scientific from $600.00 to $615.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Five analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $618.94.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.